Ultra-rare TP53 and KRAS variants predict survival in ICI-treated solid tumours
{{output}}
Background: The prognostic relevance of ultra-rare TP53 and KRAS variants in advanced solid tumours treated with immune-checkpoint inhibitors (ICI) is unclear. Me... ...
